News Archive
Peptimmune Presentation at the upcoming meeting of the American Society for Experimental NeuroTherapeutics
Details
Dr. Eric Zanelli, Vice President – Research, will make a presentation entitled "Induction of an anti-inflammatory immune response toward toxic species of alpha-synuclein; Immunomodulatory therapy for Parkinson’s Disease" in the Oral Pipeline Session on March 5, 2010 from 2:00 pm – 6:00 pm in the Haverford Suite of the Crystal Ballroom of the Hyatt Regency Bethesda, Bethesda Maryland.
About DEEP
DEEP is a peptide copolymer technology that anticipates antigenic diversity while preserving specificity for the epitope of interest. DEEP takes advantage of Peptimmune’s know-how in the solid-phase manufacturing of complex peptide mixtures. The technology combines the epitope specificity of a fixed-sequence peptide with the randomness of a broadly immune-interactive copolymer.
About Peptimmune
Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, please contact us.
